A citation-based method for searching scientific literature

P Ballerini, S Struski, C Cresson, N Prade, S Toujani, C Deswarte, S Dobbelstein, A Petit, H Lapillonne, E-F Gautier, C Demur, E Lippert, P Pages, V Mansat-De Mas, J Donadieu, F Huguet, N Dastugue, C Broccardo, C Perot, E Delabesse. Leukemia 2012
Times Cited: 65







List of co-cited articles
950 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


KIF5B-RET fusions in lung adenocarcinoma.
Takashi Kohno, Hitoshi Ichikawa, Yasushi Totoki, Kazuki Yasuda, Masaki Hiramoto, Takao Nammo, Hiromi Sakamoto, Koji Tsuta, Koh Furuta, Yoko Shimada,[...]. Nat Med 2012
570
63

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
Doron Lipson, Marzia Capelletti, Roman Yelensky, Geoff Otto, Alex Parker, Mirna Jarosz, John A Curran, Sohail Balasubramanian, Troy Bloom, Kristina W Brennan,[...]. Nat Med 2012
615
43

RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
896
43

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
849
38


Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
658
35

RET revisited: expanding the oncogenic portfolio.
Lois M Mulligan. Nat Rev Cancer 2014
293
32

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.
Francesca Carlomagno, Teresa Guida, Suresh Anaganti, Giancarlo Vecchio, Alfredo Fusco, Anderson J Ryan, Marc Billaud, Massimo Santoro. Oncogene 2004
182
30

PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.
M Grieco, M Santoro, M T Berlingieri, R M Melillo, R Donghi, I Bongarzone, M A Pierotti, G Della Porta, A Fusco, G Vecchio. Cell 1990
817
30

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.
L M Mulligan, J B Kwok, C S Healey, M J Elsdon, C Eng, E Gardner, D R Love, S E Mole, J K Moore, L Papi. Nature 1993
29

Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.
Thomas Wiesner, Jie He, Roman Yelensky, Rosaura Esteve-Puig, Thomas Botton, Iwei Yeh, Doron Lipson, Geoff Otto, Kristina Brennan, Rajmohan Murali,[...]. Nat Commun 2014
368
29

Structure and chemical inhibition of the RET tyrosine kinase domain.
Phillip P Knowles, Judith Murray-Rust, Svend Kjaer, Rizaldy P Scott, Sarah Hanrahan, Massimo Santoro, Carlos F Ibáñez, Neil Q McDonald. J Biol Chem 2006
174
27

Identification and characterization of RET fusions in advanced colorectal cancer.
Anne-France Le Rolle, Samuel J Klempner, Christopher R Garrett, Tara Seery, Eric M Sanford, Sohail Balasubramanian, Jeffrey S Ross, Philip J Stephens, Vincent A Miller, Siraj M Ali,[...]. Oncotarget 2015
70
27

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
Francesca Carlomagno, Donata Vitagliano, Teresa Guida, Fortunato Ciardiello, Giampaolo Tortora, Giancarlo Vecchio, Anderson J Ryan, Gabriella Fontanini, Alfredo Fusco, Massimo Santoro. Cancer Res 2002
479
26

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.
M Santoro, F Carlomagno, A Romano, D P Bottaro, N A Dathan, M Grieco, A Fusco, G Vecchio, B Matoskova, M H Kraus. Science 1995
703
26

RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.
Shumei Kato, Vivek Subbiah, Erica Marchlik, Sheryl K Elkin, Jennifer L Carter, Razelle Kurzrock. Clin Cancer Res 2017
113
26

The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
C Eng, D Clayton, I Schuffenecker, G Lenoir, G Cote, R F Gagel, H K van Amstel, C J Lips, I Nishisho, S I Takai,[...]. JAMA 1996
773
23

RET tyrosine kinase signaling in development and cancer.
Elena Arighi, Maria Grazia Borrello, Hannu Sariola. Cytokine Growth Factor Rev 2005
306
23

Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies.
Daniela Bossi, Francesca Carlomagno, Isabella Pallavicini, Giancarlo Pruneri, Maurizio Trubia, Paola Rafaniello Raviele, Alessandra Marinelli, Suresh Anaganti, Maria Christina Cox, Giuseppe Viale,[...]. Mol Oncol 2014
22
68

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
Alexander Drilon, Zishuo I Hu, Gillianne G Y Lai, Daniel S W Tan. Nat Rev Clin Oncol 2018
134
23

RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.
Rui Wang, Haichuan Hu, Yunjian Pan, Yuan Li, Ting Ye, Chenguang Li, Xiaoyang Luo, Lei Wang, Hang Li, Yang Zhang,[...]. J Clin Oncol 2012
347
21

RET fusion as a novel driver of medullary thyroid carcinoma.
Elizabeth G Grubbs, Patrick Kwok-Shing Ng, Jacquelin Bui, Naifa L Busaidy, Ken Chen, Jeffrey E Lee, Xinyan Lu, Hengyu Lu, Funda Meric-Bernstam, Gordon B Mills,[...]. J Clin Endocrinol Metab 2015
48
29

Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
H Donis-Keller, S Dou, D Chi, K M Carlson, K Toshima, T C Lairmore, J R Howe, J F Moley, P Goodfellow, S A Wells. Hum Mol Genet 1993
20

BAY 43-9006 inhibition of oncogenic RET mutants.
Francesca Carlomagno, Suresh Anaganti, Teresa Guida, Giuliana Salvatore, Giancarlo Troncone, Scott M Wilhelm, Massimo Santoro. J Natl Cancer Inst 2006
408
20

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.
Alexander Drilon, Lu Wang, Adnan Hasanovic, Yoshiyuki Suehara, Doron Lipson, Phil Stephens, Jeffrey Ross, Vincent Miller, Michelle Ginsberg, Maureen F Zakowski,[...]. Cancer Discov 2013
347
20

Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Luca Mologni, Sara Redaelli, Andrea Morandi, Ivan Plaza-Menacho, Carlo Gambacorti-Passerini. Mol Cell Endocrinol 2013
62
20

Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.
Qingling Huang, Valentina E Schneeberger, Noreen Luetteke, Chengliu Jin, Roha Afzal, Mikalai M Budzevich, Rikesh J Makanji, Gary V Martinez, Tao Shen, Lichao Zhao,[...]. Mol Cancer Ther 2016
52
25

A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Cristina Romei, Raffaele Ciampi, Rossella Elisei. Nat Rev Endocrinol 2016
162
20

Selective RET kinase inhibition for patients with RET-altered cancers.
V Subbiah, V Velcheti, B B Tuch, K Ebata, N L Busaidy, M E Cabanillas, L J Wirth, S Stock, S Smith, V Lauriault,[...]. Ann Oncol 2018
186
20

RET rearrangements are actionable alterations in breast cancer.
Bhavna S Paratala, Jon H Chung, Casey B Williams, Bahar Yilmazel, Whitney Petrosky, Kirstin Williams, Alexa B Schrock, Laurie M Gay, Ellen Lee, Sonia C Dolfi,[...]. Nat Commun 2018
52
25

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.
Vivek Subbiah, Justin F Gainor, Rami Rahal, Jason D Brubaker, Joseph L Kim, Michelle Maynard, Wei Hu, Qiongfang Cao, Michael P Sheets, Douglas Wilson,[...]. Cancer Discov 2018
195
20

A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.
R M Hofstra, R M Landsvater, I Ceccherini, R P Stulp, T Stelwagen, Y Luo, B Pasini, J W Höppener, H K van Amstel, G Romeo. Nature 1994
942
18

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Rossella Elisei, Barbara Cosci, Cristina Romei, Valeria Bottici, Giulia Renzini, Eleonora Molinaro, Laura Agate, Agnese Vivaldi, Pinuccia Faviana, Fulvio Basolo,[...]. J Clin Endocrinol Metab 2008
319
18

Structure and physiology of the RET receptor tyrosine kinase.
Carlos F Ibáñez. Cold Spring Harb Perspect Biol 2013
98
18

The landscape of kinase fusions in cancer.
Nicolas Stransky, Ethan Cerami, Stefanie Schalm, Joseph L Kim, Christoph Lengauer. Nat Commun 2014
568
18

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Oliver Gautschi, Julie Milia, Thomas Filleron, Juergen Wolf, David P Carbone, Dwight Owen, Ross Camidge, Vignhesh Narayanan, Robert C Doebele, Benjamin Besse,[...]. J Clin Oncol 2017
195
18

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Kiyotaka Yoh, Takashi Seto, Miyako Satouchi, Makoto Nishio, Noboru Yamamoto, Haruyasu Murakami, Naoyuki Nogami, Shingo Matsumoto, Takashi Kohno, Koji Tsuta,[...]. Lancet Respir Med 2017
200
18

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Razelle Kurzrock, Steven I Sherman, Douglas W Ball, Arlene A Forastiere, Roger B Cohen, Ranee Mehra, David G Pfister, Ezra E W Cohen, Linda Janisch, Forlisa Nauling,[...]. J Clin Oncol 2011
407
16

A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.
Young Seok Ju, Won-Chul Lee, Jong-Yeon Shin, Seungbok Lee, Thomas Bleazard, Jae-Kyung Won, Young Tae Kim, Jong-Il Kim, Jin-Hyoung Kang, Jeong-Sun Seo. Genome Res 2012
345
16

Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.
I Plaza-Menacho, A Morandi, D Robertson, S Pancholi, S Drury, M Dowsett, L-A Martin, C M Isacke. Oncogene 2010
96
16


Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret.
A Schuchardt, V D'Agati, L Larsson-Blomberg, F Costantini, V Pachnis. Nature 1994
16

RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.
Massimo Santoro, Rosa Marina Melillo, Alfredo Fusco. Eur J Endocrinol 2006
135
16


Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Alexander Drilon, Natasha Rekhtman, Maria Arcila, Lu Wang, Andy Ni, Melanie Albano, Martine Van Voorthuysen, Romel Somwar, Roger S Smith, Joseph Montecalvo,[...]. Lancet Oncol 2016
272
16

Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.
Samuel A Wells, Furio Pacini, Bruce G Robinson, Massimo Santoro. J Clin Endocrinol Metab 2013
180
15

Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B.
Taranjit S Gujral, Vinay K Singh, Zongchao Jia, Lois M Mulligan. Cancer Res 2006
55
18

The neurotrophic factor receptor RET drives haematopoietic stem cell survival and function.
Diogo Fonseca-Pereira, Sílvia Arroz-Madeira, Mariana Rodrigues-Campos, Inês A M Barbosa, Rita G Domingues, Teresa Bento, Afonso R M Almeida, Hélder Ribeiro, Alexandre J Potocnik, Hideki Enomoto,[...]. Nature 2014
65
15

Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers.
Julio C Ricarte-Filho, Sheng Li, Maria E R Garcia-Rendueles, Cristina Montero-Conde, Francesca Voza, Jeffrey A Knauf, Adriana Heguy, Agnes Viale, Tetyana Bogdanova, Geraldine A Thomas,[...]. J Clin Invest 2013
144
15

Central role of RET in thyroid cancer.
Massimo Santoro, Francesca Carlomagno. Cold Spring Harb Perspect Biol 2013
67
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.